Opportunity
NEW – STX Specialized Molecular Residual Disease Testing
Response due
October 30, 2026
- Agency
- 257-NETWORK Contract Office 17 (36C257)
- Estimated value
- Not stated
Special Notice Special Notice Page 3 of 3 Special Notice *= Required Field Special Notice Page 1 of 3 1. NOTICE OF INTENT DESCRIPTION The Department of Veterans Affairs, Network Contracting Office (NCO) 17, located at 5441 Babcock Road, Suite 302, San Antonio, TX 78229, intends to award an Indefinite Delivery Indefinite Quantity (IDIQ) Firm Fixed Price contract with five ordering periods on a sole-source basis to: Natera, Inc. 13011 McCallen Pass Austin, TX 78752 This requirement is for proprietary molecular genetic reference testing services used in the evaluation and monitoring of transplant patients and cancer residual disease. 2. SUPPLIES/SERVICES Item 0001 Description: Signatera Only, CPT Codes 81479, 81455 Estimated Quantity: 35 Unit: Each Item 0002 Description: Prospera, CPT Code 81479 Estimated Quantity: 25 Unit: Each Natera is the sole provider of these proprietary medical laboratory tests, including: Prospera molecular expression transplant assessment test Signatera Residual Disease Test (MRD) (non liquid biopsy tumor typing) No other vendor possesses the proprietary methodologies, assays, or intellectual property required to perform these tests. 3. SOLE SOURCE JUSTIFICATION Testing required by the VA is proprietary to Natera, Inc. No authorized distributors, third party laboratories, or alternative clinical sources exist for the Prospera and Signatera MRD tests. These assays cannot be substituted or performed by any other laboratory. Only Natera maintains the necessary technology, reagents, and bioinformatics platforms. 4. THIS NOTICE IS NOT A REQUEST FOR QUOTES This Special Notice is issued solely for information and planning purposes. It does not constitute a solicitation or a request for competitive quotes. Interested parties may submit a capability statement demonstrating an ability to perform the required testing. Responses must clearly show that an equivalent proprietary test exists and can be provided. 5. RESPONSE INSTRUCTIONS Responses must be emailed to: Susan Flores Contract Specialist, NCO 17 Email: Susan.Flores2@va.gov Deadline: November 2, 2026 at 10:00 AM CST The Government will review all responses but retains discretion regarding whether to compete this requirement. The Government is not responsible for any costs incurred in responding to this notice. 6. PLACE OF PERFORMANCE VA Facilities within VISN 17 (Texas) Specific ordering locations will be identified in individual task/delivery orders. 7. PERIOD OF PERFORMANCE Five ordering periods (exact dates to be determined at award).
Key dates
- Posted
- October 22, 2026
- Response due
- October 30, 2026
Who is this buyer
Organization
Buying history
- Records384 total
- Opportunities / awards4 / 245
- Value range$0 – $35,722,589
- ActiveMay 1, 2026 – October 24, 2026
What they buy
- Clinical (345)
- Administrative (39)
Set-asides used
- SDVOSB Set-Aside (FAR 19.14) (30)
- Small Business Set Aside - Total (24)
- No Set aside used (18)
- SDVOSB Sole Source (FAR 19.14) (7)
Who holds their work today
- PRIMARY CARE SOLUTIONS INC10 wins · $43,846,560 · last October 1, 2026
- VALOR HEALTHCARE INC9 wins · $38,463,715 · last September 13, 2026
- POTOMAC VALOR HEALTHCARE 2, LLC6 wins · $35,632,398 · last August 12, 2026
- JADE WOLF OPERATIONS, LLC1 win · $14,351,033 · last March 1, 2023
- LABORATORY CORPORATION OF AMERICA6 wins · $12,093,420 · last May 1, 2026
Also open from this buyer
- Sterile Compounding ServicesDue November 4, 2026 · Clinical
- SterilizerDue November 3, 2026 · Clinical
- Human Blood and Blood ProductsDue November 5, 2026 · Clinical
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- Not stated
- NAICS
- 621511
- PSC
- Q301